Link:
Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19

– Pharmacodynamic results confirm localized exoIL-12 pharmacologic activity

Read the original post:
Codiak Reports Additional Positive Phase 1 Results for exoIL-12™ Confirming Local Pharmacology and Dose Selection for Safety and Efficacy Trial...

Orphazyme USInvestor news                                                                                                         No. 02/2021

Read the rest here:
Orphazyme to showcase data on arimoclomol in Niemann-Pick disease Type C during the 2021 Annual WORLDSymposium™

MONTREAL, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that the United States Food and Drug Administration (FDA) has granted fast track designation to TH1902 as a single agent for the treatment of patients with sortilin positive recurrent advanced solid tumors that are refractory to standard therapy.

See the original post here:
Theratechnologies’ Lead Peptide Drug Conjugate TH1902 Receives FDA Fast Track Designation for the Treatment of Sortilin-expressing Cancers

SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and full year 2020 and provide a corporate update at 4:30 p.m. ET on February 11, 2021.

Read the rest here:
Otonomy to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will participate in the Guggenheim Healthcare Talks: 2021 Oncology Day conference. The fireside chat will take place on February 11, 2021 at 2:00 PM ET. This meeting is being held virtually, and a live webcast will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.

Original post:
G1 Therapeutics to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day Virtual Conference

SANTA ANA, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies, announced the appointment of Stephen Chen, MBA to Chief Operating Officer (COO).

More:
NKMax America Announces Key Leadership Appointment

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that an expanded access protocol (EAP) for Oxbryta® (voxelotor) in pediatric patients with sickle cell disease (SCD) has been initiated and is currently enrolling. The EAP is designed to provide access to Oxbryta prior to approval for children ages 4 to 11 years with SCD in the United States who have no alternative treatment options and are ineligible to participate in clinical trials of Oxbryta. GBT enrolled its first patient in the EAP in January 2021.

Originally posted here:
GBT Initiates Expanded Access Protocol for Oxbryta® (voxelotor) in Pediatric Patients with Sickle Cell Disease in the United States

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in a virtual fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day on February 11th at 3:30 p.m. ET. In addition, management will be available for one-on-one meetings with investors.

Excerpt from:
CytomX Therapeutics to Present at Guggenheim Healthcare Talks 2021 Oncology Day

BETHESDA, Md., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced that it will present three late-breaker abstracts at the 17th annual WORLDSymposium, a research conference dedicated to lysosomal diseases being held virtually February 8-12, 2021. The poster presentations will highlight data supporting Gain’s Gaucher disease, GM1 gangliosidosis and Morquio B programs.

See original here:
Gain Therapeutics Announces Three Late-Breaker Presentations at the 17th Annual WORLDSymposium

RP1: Initial data in new indications expected in 2021 in anti-PD1 failed NSCLC, anti-PD1 failed CSCC and CSCC solid organ transplant recipient patients; further updates expected to be provided across all studies

Read the rest here:
Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update

Company to Participate in Two Q&A Sessions, Including a Joint Discussion with Zai Lab Company to Participate in Two Q&A Sessions, Including a Joint Discussion with Zai Lab

View original post here:
Turning Point Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days

LEXINGTON, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced positive preliminary results from its Phase 1 trial of iNKT cell therapy in patients with moderate to severe symptoms of COVID-19 through its subsidiary, AgenTus Therapeutics.

Continue reading here:
Agenus Announces Positive Preliminary Results of iNKT Cell Therapy Trial in COVID-19

Overallotment option on recent public offering partially exercised by underwriter

More here:
Outlook Therapeutics’ Recent Financing Secures Funding to Support ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Through Planned BLA Submission

Milestone Marks Advance for Oral Mucosal Immunotherapy for Peanut Allergies Milestone Marks Advance for Oral Mucosal Immunotherapy for Peanut Allergies

The rest is here:
Intrommune Receives IND Clearance From U.S. Food and Drug Administration for INT301

CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc., (Alphageneron) signed an Exclusive License Agreement with Multimmune GmbH, of Munich, Germany, (Multimmune) on October 1st, 2020, for its clinical stage autologous Natural Killer (“NK”) cell therapy and companion diagnostic platform, for all fields worldwide.

Continue reading here:
Alphageneron Pharmaceuticals Signed Exclusive License Agreement With Multimmune GmbH For Natural Killer Cell Platform Therapy Worldwide

Article reflects Company’s leadership and innovation in scalable, reproducible manufacture of adeno-associated virus (AAV)-based gene therapies

More here:
AGTC Executives Awarded First Place in the BioProcess International Reader’s Choice Awards, Cell & Gene Therapies Category

Read more:
Monthly information related to total number of voting rights and shares composing the share capital – January 31, 2021

RALEIGH, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and full year 2020 results after the market closes on Thursday, February 25, 2021. The Company will also host a conference call on Friday, February 26, 2021 at 9:00 a.m. (ET) to discuss the results with members of the investment community.

See the rest here:
PRA Health Sciences to Report Fourth Quarter and Full Year 2020 Earnings

Researchers at the Catholic University of Korea St. Marys Hospital have recently proved the efficacy of bone marrow-derived stem cells to treat ototoxicity hearing loss, the hospital said Thursday.

The team, led by Professor Park Kyoung-ho of the Department of Otolaryngology, conducted an experiment on animal models with ototoxic sensorineural hearing, or sudden hearing loss.

They utilized Catholic MASTER cells, bone marrow stem cells developed by the Catholic Institute of Cell Therapy, to compare the stem cell injection group with the controlled group.

The result showed that animals started to recover their hearing after three weeks. Five weeks later, they recovered normal hearing at 8000Hz, 16000Hz and 32000Hz frequency.

Ototoxic hearing loss is caused when a person ingests chemicals or certain medications that adversely affect the inner ear functions. Major symptoms related to the illness are dizziness, false hearing, and hearing loss, which permanently defects hearing functions. Elders with such symptoms should have medical consultations as they are a high-risk group, the hospital said.

We have proved the efficacy of our bone marrow stem cells in recovering hearing, said Professor Park, who doubles as the director of the Stem Cell Institute. Through the results, we expect to provide new treatment opportunities for patients with hearing loss.

The test results were published in the Korean Journal of Otorhinolaryngology-Head and Neck Surgery.

Original post:
Stem cells efficacy confirmed in treating ototoxic hearing loss - Korea Biomedical Review